ReviewBritish journal of pharmacology2006
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.
Review in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 77 citations in OpenAlex.
- Exploring TGF-β signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications.Biogerontology · 2025Review
- Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach.Biomedicines · 2023Review
- Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models.International journal of molecular sciences · 2023Review
- Article
- The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment.Journal of xenobiotics · 2021Review
- Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonistInternational journal of cancer · 2019Article
- TRPM2 mediates distruption of autophagy machinery and correlates with the grade level in prostate cancer.Journal of cancer research and clinical oncology · 2019Article
- The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.Molecular medicine (Cambridge, Mass.) · 2018Article
- Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.The Journal of steroid biochemistry and molecular biology · 2017Review
- Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.Molecular endocrinology (Baltimore, Md.) · 2015Article
- Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors.Oncogenesis · 2015Article
- Article
- The effects of self-assembling peptide RADA16 hydrogel on malignant phenotype of human hepatocellular carcinoma cell.International journal of clinical and experimental medicine · 2015Article
- Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.Histochemistry and cell biology · 2014Article
- TGF-β cascade regulation by PPP1 and its interactors -impact on prostate cancer development and therapy.Journal of cellular and molecular medicine · 2014Review
- Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer.Molecular cancer · 2014Article
- Prostate cancer: the need for biomarkers and new therapeutic targets.Journal of Zhejiang University. Science. B · 2014Review
- Role of p38 MAP Kinase Signal Transduction in Solid Tumors.Genes & cancer · 2013Review
- Autophagy in prostate cancer and androgen suppression therapy.International journal of molecular sciences · 2013Review
- Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?Hepatology international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The intricate balance maintained between cell growth and proliferation factors and apoptosis-inducing factors is fundamental to the regulation of prostate growth. Disruptions in this homeostasis often trigger the loss of apoptosis and the over-expression of factors promoting cell survival and proliferation, inevitably leading to tumorigenesis and cancer. Deregulation of prostate growth during prostate cancer development and progression is characterized by apoptotic evasion, uncontrolled proliferation, and increased invasive potential. Thus, in advanced stages of disease progression, surviving prostate tumour cells acquire the ability to migrate and invade heterotopic tissues, with the bone and lymph nodes being the most common sites for human prostate cancer metastasis. The challenges in the implementation of effective therapeutic strategies for the treatment of advanced metastatic prostate cancer reflect the multidimensional nature and functional significance of antiapoptotic pathways in the emergence of therapeutic resistance of prostate tumours. In this chapter, we discuss the current understanding of the molecular mechanisms governing growth factor signalling pathways with often overlapping functions that contribute to loss of apoptosis control and activation of cell proliferation towards aggressive prostate tumorigenic growth and metastatic behaviour. While a full understanding of the prosurvival characteristics of these growth factor pathways is still evolving, the impact that growth factors such a epidermal growth factor and transforming growth factor-beta can be recognized by the vigorous attempts at therapeutic targeting of their key signalling steps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.